Valion Bio Appoints Melinda Lackey as General Counsel

The latest announcement is out from Valion Bio ( (VBIO) ).

On May 4, 2026, Valion Bio appointed biopharmaceutical attorney Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs, following the execution of her employment agreement on May 1, 2026. Lackey, who brings nearly two decades of scientific, intellectual property and public company legal experience from roles at Alaunos Therapeutics, Kuur Therapeutics and major law firms, will oversee legal and governance matters as the company advances its immunotherapeutic programs and CDMO operations.

Her compensation package includes a $321,000 annual base salary, eligibility for a performance-based bonus and equity incentives, as well as a stock option grant for 45,000 shares, with standard at-will employment and defined severance protections for termination without cause or for good reason. The hire strengthens Valion Bio’s internal legal capabilities at a pivotal stage as it pursues an FDA Animal Rule approval path for Entolimod™, executes capital-raising plans and scales its Velocity Bioworks manufacturing subsidiary, moves that could bolster regulatory execution and risk management for shareholders and partners.

Spark’s Take on VBIO Stock

According to Spark, TipRanks’ AI Analyst, VBIO is a Neutral.

The score is primarily constrained by very weak financial performance (shrinking revenue, persistent losses, negative cash flow, and significant balance-sheet erosion). Technicals are mixed but generally pressured by longer-term downtrends, while valuation is hard to support due to negative earnings and no dividend data.

To see Spark’s full report on VBIO stock, click here.

More about Valion Bio

Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) is a Nasdaq-listed, clinical-stage immunotherapeutics company developing Entolimod™, a TLR5 agonist, for Acute Radiation Syndrome via the FDA Animal Rule pathway, oncology supportive care and longevity indications. The company is also advancing next-generation TLR5 agonist Entolasta™ and operates Velocity Bioworks, a San Antonio-based CDMO providing biomanufacturing services to third-party biotech clients.

Through its combination of a clinical-stage pipeline, government-aligned countermeasures program and in-house manufacturing via Velocity Bioworks, Valion Bio is positioning itself as both a drug developer and a service provider in immunotherapy and advanced biologics. Its programs benefit from Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration, underscoring their potential strategic value in radiation countermeasures and supportive oncology care.

Average Trading Volume: 264,364

Technical Sentiment Signal: Sell

Current Market Cap: $2.65M

See more insights into VBIO stock on TipRanks’ Stock Analysis page.